{"id":"https://openalex.org/W4310102718","doi":"https://doi.org/10.1182/blood-2022-163778","title":"Impact of Pegcetacoplan on Paroxysmal Nocturnal Hemoglobinuria Symptoms in Patients Previously Treated with C5-Inhibitors","display_name":"Impact of Pegcetacoplan on Paroxysmal Nocturnal Hemoglobinuria Symptoms in Patients Previously Treated with C5-Inhibitors","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310102718","doi":"https://doi.org/10.1182/blood-2022-163778"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-163778","doi":"https://doi.org/10.1182/blood-2022-163778","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-163778","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080314729","display_name":"Dharmik Desai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120540","display_name":"Apellis Pharmaceuticals (United States)","ror":"https://ror.org/0231n7e68","country_code":"US","type":"company","lineage":["https://openalex.org/I4210120540"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dharmik Desai","raw_affiliation_strings":["1Apellis Pharmaceuticals, Inc., Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apellis Pharmaceuticals, Inc., Waltham, MA","institution_ids":["https://openalex.org/I4210120540"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077321428","display_name":"Nandini Hadker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nandini Hadker","raw_affiliation_strings":["2Trinity Life Sciences, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Trinity Life Sciences, Waltham, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Matthew O'Hara","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew O'Hara","raw_affiliation_strings":["2Trinity Life Sciences, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Trinity Life Sciences, Waltham, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Laura Hill","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laura Hill","raw_affiliation_strings":["2Trinity Life Sciences, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Trinity Life Sciences, Waltham, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054112773","display_name":"Jed Perler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jed Perler","raw_affiliation_strings":["2Trinity Life Sciences, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Trinity Life Sciences, Waltham, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007747233","display_name":"David Dingli","orcid":"https://orcid.org/0000-0001-7477-3004","observed_orcids":["https://orcid.org/0000-0001-7477-3004"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Dingli","raw_affiliation_strings":["3Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.14771302,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"140","issue":"Supplement 1","first_page":"11443","last_page":"11444"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/paroxysmal-nocturnal-hemoglobinuria","display_name":"paroxysmal nocturnal hemoglobinuria","score":0.9940000176429749},{"id":"https://openalex.org/keywords/pegcetacoplan","display_name":"pegcetacoplan","score":0.9980000257492065},{"id":"https://openalex.org/keywords/c3-inhibitor","display_name":"C3 inhibitor","score":0.8240000009536743},{"id":"https://openalex.org/keywords/c5-inhibitor","display_name":"C5 inhibitor","score":0.8629999756813049},{"id":"https://openalex.org/keywords/eculizumab","display_name":"eculizumab","score":0.9860000014305115},{"id":"https://openalex.org/keywords/ravulizumab","display_name":"ravulizumab","score":1.0},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.8259999752044678},{"id":"https://openalex.org/keywords/cognitive-symptoms","display_name":"cognitive symptoms","score":0.9150000214576721},{"id":"https://openalex.org/keywords/dyspnea","display_name":"dyspnea","score":0.9120000004768372},{"id":"https://openalex.org/keywords/muscle-weakness","display_name":"muscle weakness","score":0.6439999938011169},{"id":"https://openalex.org/keywords/gastrointestinal-symptoms","display_name":"gastrointestinal symptoms","score":0.9240000247955322},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.7860000133514404},{"id":"https://openalex.org/keywords/patient-experience","display_name":"patient experience","score":0.5899999737739563},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.5630000233650208},{"id":"https://openalex.org/keywords/complement-inhibition","display_name":"complement inhibition","score":0.3409999907016754}],"concepts":[{"id":"https://openalex.org/C2777346216","wikidata":"https://www.wikidata.org/wiki/Q1479494","display_name":"Paroxysmal nocturnal hemoglobinuria","level":2,"score":0.9252505302429199},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9048033952713013},{"id":"https://openalex.org/C2777991916","wikidata":"https://www.wikidata.org/wiki/Q421617","display_name":"Eculizumab","level":4,"score":0.778207004070282},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.5178318619728088},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.5083720088005066},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4972694218158722},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.4655865728855133},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.439573734998703},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.11700397729873657},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.10257801413536072},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C111684460","wikidata":"https://www.wikidata.org/wiki/Q334848","display_name":"Complement system","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-163778","doi":"https://doi.org/10.1182/blood-2022-163778","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-163778","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4386282191","https://openalex.org/W4288085784","https://openalex.org/W4405050835","https://openalex.org/W3097000093","https://openalex.org/W4385655000","https://openalex.org/W4389248451","https://openalex.org/W4310105223","https://openalex.org/W4296468447","https://openalex.org/W4389259318","https://openalex.org/W7108488815"],"abstract_inverted_index":{"Background":[0],"Paroxysmal":[1],"nocturnal":[2],"hemoglobinuria":[3],"(PNH)":[4],"is":[5,63,170,177,480,528],"a":[6,164,198,214,292,298,305,326],"rare,":[7],"acquired":[8],"hematologic":[9],"condition":[10],"associated":[11],"with":[12,38,73,78,131,148,158,213,288],"significant":[13],"morbidity,":[14],"mortality,":[15],"and":[16,36,53,58,62,75,108,149,175,189,208,265,286,294,307,314,320,322,328,369,389,394,402,410,417,421,425,452,463,466,470,478,500,513,534],"impact":[17,100],"on":[18,103,163,249,297,347,351,381,433,476,498,526],"health-related":[19],"quality":[20],"of":[21,33,93,101,117,155,201,227,233,236,241,259,310,359,407,440,449,503,523,540],"life":[22],"(HRQoL).":[23],"In":[24,269],"the":[25,27,51,64,99,115,118,134,520,538],"past,":[26],"treatment":[28,37,87,156,212,532],"paradigm":[29],"for":[30,70,88,136],"PNH":[31,74,79,104,132,246,276,342,378,495,524],"consisted":[32],"blood":[34],"transfusions":[35],"complement":[39],"component":[40],"C5":[41,85],"inhibitors":[42],"(C5-is),":[43],"eculizumab":[44],"or":[45,172,179],"ravulizumab.":[46],"Pegcetacoplan":[47],"was":[48,96],"approved":[49,66],"in":[50,55,110,114,133,386,482],"US":[52,71,135],"EU":[54,76],"May":[56],"2021":[57],"December":[59],"2021,":[60],"respectively,":[61,296],"first":[65],"C3":[67],"inhibitor":[68,86],"(C3-i)":[69],"adults":[72,77],"who":[80],"remain":[81],"anemic":[82],"despite":[83],"stable":[84],"\u22653":[89],"months.":[90],"The":[91,239],"objective":[92],"this":[94],"study":[95,123,487],"to":[97,112,144,217,219,271,273,282,334,430,445,492,510,517,530,537],"characterize":[98],"pegcetacoplan":[102,228,348,479],"symptom":[105,284,387,474,505],"incidence,":[106,511],"frequency,":[107,512],"severity":[109,514],"comparison":[111],"C5-is":[113,333,477,499],"Voice":[116],"Patient.":[119],"Methods":[120],"This":[121,486],"mixed-methods":[122],"enrolled":[124],"consenting,":[125],"adult":[126],"patients":[127,186,196,223,242,278,337,383,490,525],"(>21":[128],"years":[129,203],"old)":[130],"telephone":[137],"depth":[138],"interviews.":[139],"Eligible":[140],"participants":[141],"were":[142,161,458],"required":[143],"be":[145],"currently":[146],"treated":[147],"have":[150],"at":[151],"least":[152],"3":[153],"months":[154,226,235],"experience":[157,229,274,432,475,493,522],"pegcetacoplan.":[159,220,518],"Symptoms":[160],"described":[162,279],"7-point":[165,299],"Likert":[166,300],"scale":[167],"(where":[168],"1":[169],"\"infrequent\"":[171],"\"very":[173,180],"mild\"":[174],"7":[176,190],"\"always\"":[178],"severe\").":[181],"Results":[182,183],"from":[184,332],"15":[185],"(8":[187],"female":[188],"male)":[191],"are":[192],"reported":[193,244,338,384,438,459],"here.":[194],"Enrolled":[195],"had":[197,210,224],"median":[199],"age":[200],"40":[202],"(range":[204],"24":[205],"-":[206],"77)":[207],"all":[209],"received":[211],"C5-i":[215,237],"prior":[216],"switching":[218,331,444,516],"On":[221],"average,":[222],"5.6":[225],"following":[230],"an":[231],"average":[232],"29.3":[234],"experience.":[238],"majority":[240],"(n=14)":[243],"experiencing":[245,280,339],"symptoms":[247,256,303,324,354,379,400,442,496],"while":[248,497],"C5-is,":[250],"most":[251],"notably":[252],"fatigue":[253,289,345,392],"(n=14),":[254],"cognitive":[255,302,353,399],"(n=12),":[257,261],"shortness":[258,309,358,406,448],"breath":[260,311,360,408,450],"muscle":[262,316,364,414,453],"weakness":[263,317,365,415,454],"(n=8),":[264],"gastrointestinal":[266,370,422],"problems":[267,371,423],"(n=8).":[268],"addition":[270],"continuing":[272],"these":[275,340,457],"symptoms,":[277,343],"moderate":[281],"high":[283],"frequency":[285,388],"severity,":[287,390],"estimated":[290],"as":[291,304,312,318,325,460,507],"6.0":[293],"5.5,":[295],"scale,":[301],"5.4":[306,319],"4.8,":[308,315],"5.1":[313],"4.6,":[321],"GI":[323],"5.3":[327],"4.9.":[329],"After":[330],"pegcetacoplan,":[335,382,446],"fewer":[336],"residual":[341,494],"including":[344,391,447],"(n=12":[346],"vs":[349,356,362,367,373],"n=14":[350],"C5-is),":[352],"(n=11":[355],"n=12),":[357,363],"(n=7":[361],"(n=5":[366,372],"n=8),":[368],"n=8)":[374],"(Figure":[375],"1).":[376],"While":[377],"persisted":[380],"reduction":[385],"(-21%":[393],"-33%":[395],"relative":[396,404,412,419,427],"reduction,":[397],"respectively),":[398],"(-16%":[401,424],"-18%":[403],"reduction),":[405,413,420],"(-30%":[409],"-31%":[411],"(-18%":[416],"-14%":[418,426],"reduction)":[428],"compared":[429],"their":[431],"C5-is.":[434],"Select":[435],"patients,":[436],"however,":[437],"onset":[439],"new":[441],"after":[443,515],"(n=1/15)":[451],"(n=1/15),":[455],"though":[456],"infrequent":[461],"(1.0":[462,469],"2.0,":[464],"respectively)":[465],"very":[467],"mild":[468],"1.0,":[471],"respectively).":[472],"Patient-reported":[473],"summarized":[481],"Figure":[483,542],"2.":[484],"Conclusions":[485],"revealed":[488],"that":[489],"continue":[491],"describes":[501],"improvement":[502],"patients'":[504],"management":[506],"it":[508],"relates":[509],"Characterizing":[519],"real-world":[521],"therapy":[527],"essential":[529],"optimizing":[531],"options":[533],"tailoring":[535],"therapies":[536],"needs":[539],"patients.":[541],"1View":[543,546],"largeDownload":[544,547],"PPTFigure":[545],"PPT":[548],"Close":[549],"modal":[550]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-11-30T00:00:00"}